NEJM: Is severe asthma still difficult to treat?

Asthma is a common lung disease.

Recently, a phase 3 clinical trial published in the New England Journal of Medicine showed that tezepelumab can effectively relieve severe asthma caused by various reasons.

Tezepelumab is a monoclonal antibody that blocks the effects of thymic stromal lymphopoietin (TSLP).

The study recruited 1061 patients between 12 and 80 years old, and the researchers randomized them.

After one year of treatment, compared with patients taking placebo, patients taking tezepelumab had less asthma, better lung function, asthma control, and health-related quality of life.

The annualized rate of acute asthma attacks in the Tezepelumab group was 0.

▲Tezepelumab can effectively relieve severe asthma.

In addition, regardless of the specific problem that caused the asthma, the patient's condition will be improved:

Compared with placebo, patients whose blood eosinophil count was less than 300 cells per microliter had a 41% reduction in asthma attacks after tezepelumab (RR = 0.

People affected by seasonal allergies had a 58% reduction in asthma attacks (RR=0.

At week 52, compared with placebo, tezepelumab increased the forced expiratory volume in the first second by 0.

In addition, the paper pointed out that tezepelumab is proven to be safe and has no obvious side effects.

references:

[1] New drug shows promise against tough-to-manage asthma.

[2] Menzies-Gow, A.